Fauci Murderer

PUBLISHED: 6:38 PM 10 Jun 2021

Fauci Murderer! HCQ Actions Deliberately Killed Hundreds Of Thousands, New Study Shows Vax “No Benefit”

This man has a history of pushing drugs that kill.

Arrest him. (Source: YouTube Screenshot)

Many people are arguing that Anthony Fauci should be arrested for crimes against humanity, specifically murder.

The Gateway Pundit explained:

Collateral Damage. That’s the new definition for the US Coronavirus deaths.

The Gateway Pundit has reported extensively this past year on the effects of hydroxychloroquine in treating the COVID-19 virus.

We knew and reported that Dr. Tony Fauci and the medical elites conspired to ban the use of this very successful drug.

We reported earlier on how Dr. Fauci used bogus studies to disqualify HCQ in treating coronavirus.

We also reported that there is proof that Dr. Fauci and top US medical experts all conspired using obviously false information to disqualify hydroxychloroquine and MILLIONS DIED as a result of their action.

A new study released this June revealed at medRxiv suggests that the use of weight-adjusted Hydroxychloroquine (HCQ) and Azithromycin (AZM) appears to be associated with a more than 100% increase in survival, without a clear correlation with ECG abnormalities.

President Trump called this out back in March 2020.

Trump actually promoted the HCQ and AZM combination one year ago!

But Dr. Fauci, the media, the far left tech giants, and Democrats mocked him and disputed this treatment.
They blocked, censored and ridiculed anyone who promoted this successful treatment.

They blocked, censored and banned Gateway Pundit reports on this successful treatment.

And hundreds of thousands of Americans died.
Collateral damage.

And now, a new study has determined that there’s no need for the dna-altering vaccine.

Conservative Treehouse explained:

As many people suspected, there is now a study from the Cleveland Clinic [SEE HERE] showing there is no need to vaccinate anyone who previously recovered from the COVID-19 virus.  The vaccination provides no additional benefit.

CLEVELAND CLINIC – ♦ Conclusions – Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.

♦ Summary – Cumulative incidence of COVID-19 was examined among 52238 employees in an American healthcare system. COVID-19 did not occur in anyone over the five months of the study among 2579 individuals previously infected with COVID-19, including 1359 who did not take the vaccine. (details)

The Study Found:

ABSTRACT
Background The purpose of this study was to evaluate the necessity of COVID-19 vaccination in persons previously infected with SARS-CoV-2.

Methods Employees of the Cleveland Clinic Health System working in Ohio on Dec 16, 2020, the day COVID-19 vaccination was started, were included. Any subject who tested positive for SARS-CoV-2 at least 42 days earlier was considered previously infected. One was considered vaccinated 14 days after receipt of the second dose of a SARS-CoV-2 mRNA vaccine. The cumulative incidence of SARS-CoV-2 infection over the next five months, among previously infected subjects who received the vaccine, was compared with those of previously infected subjects who remained unvaccinated, previously uninfected subjects who received the vaccine, and previously uninfected subjects who remained unvaccinated.

Results Among the 52238 included employees, 1359 (53%) of 2579 previously infected subjects remained unvaccinated, compared with 22777 (41%) of 49659 not previously infected. The cumulative incidence of SARS-CoV-2 infection remained almost zero among previously infected unvaccinated subjects, previously infected subjects who were vaccinated, and previously uninfected subjects who were vaccinated, compared with a steady increase in cumulative incidence among previously uninfected subjects who remained unvaccinated. Not one of the 1359 previously infected subjects who remained unvaccinated had a SARS-CoV-2 infection over the duration of the study. In a Cox proportional hazards regression model, after adjusting for the phase of the epidemic, vaccination was associated with a significantly lower risk of SARS-CoV-2 infection among those not previously infected (HR 0.031, 95% CI 0.015 to 0.061) but not among those previously infected (HR 0.313, 95% CI 0 to Infinity).

Conclusions Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.

Summary Cumulative incidence of COVID-19 was examined among 52238 employees in an American healthcare system. COVID-19 did not occur in anyone over the five months of the study among 2579 individuals previously infected with COVID-19, including 1359 who did not take the vaccine.

Competing Interest Statement
The authors have declared no competing interest.

Funding Statement
There was no funding for this study.

Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was approved by the Cleveland Clinic Institutional Review Board. A waiver of informed consent and waiver of HIPAA authorization were approved to allow access to personal health information by the research team, with the understanding that sharing or releasing identifiable data to anyone other than the study team was not permitted without additional IRB approval.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes